Cycloalkyl-linked diheterocycle derivatives
US-10125130-B2 · Nov 13, 2018 · US
Cycloalkyl-linked diheterocycle derivatives
US10676471B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10676471-B2 |
| Application number | US-201916416997-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2019 |
| Priority date | Apr 30, 2014 |
| Publication date | Jun 9, 2020 |
| Grant date | Jun 9, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R 1 -R 15 , w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical formulation comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent, or excipient.
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
not condensed and containing further heterocyclic rings · CPC title
by carboxylic acids, or sulfur or nitrogen analogues thereof · CPC title
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10676471B2 cover?
- The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R 1 -R 15 , w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell…
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification C07D417/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).